200
Participants
Start Date
October 31, 2011
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2015
tasimelteon
20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
New York Eye and Ear Infirmary, New York
Consolidated Clinical trials, Pittsburgh
Center for Sleep Medicine at Chestnut Hill Hospital, Philadelphia
The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area), Chevy Chase
SleepMed, Inc. - Columbia, Columbia
Sleep Disorders Center Of Georgia, Atlanta
Neurology Associates of Ormond Beach, Ormond Beach
Kendall South Medical Center, Inc., Miami
PAB Clinical Research Inc., Brandon
Ohio Sleep Medicine Institute (Columbus Metropolitan Area), Dublin
Michigan Head-Pain Neurological Institute, Ann Arbor
Suburban Lung Associates SC (Chicago Metropolitan Area), Elk Grove Village
St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area), Chesterfield
Lynn Health Science Institute, Oklahoma City
Todd J. Swick, M.D., P.A., Houston
Radiant Research - Denver, Denver
Pulmonary Associates, PA, Phoenix
St. Johns Sleep Disorder Center - St. Johns Medical Plaza, Santa Monica
SDS Clinical Trials Inc., Orange
VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area), Palo Alto
Columbia Research Group Inc., Portland
Brigham and Women's Hospital, Boston
Lead Sponsor
Vanda Pharmaceuticals
INDUSTRY